| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02616315 | Weight Regain Post Bariatric Surgery | Drug: Naltrexone HCl/Bupropion HCl Placebo|Drug: Naltrexone HCl/Bupropion HCl | Takeda | Phase 4 | 2016-02-01 | 2016-04-07 |
| NCT01015170 | Cigarette Smoking|Nicotine Addiction|Smoking Cessation | Drug: bupropion HCl | Centre for Addiction and Mental Health|Ontario Ministry of Health and Long Term Care | Phase 4 | 2009-10-01 | 2017-02-07 |
| NCT02638129 | Obesity|Cardiovascular Diseases | Drug: Naltrexone HCl/Bupropion HCl ER|Drug: Placebo | Orexigen Therapeutics, Inc | Phase 4 | 2016-01-01 | 2017-02-21 |
| NCT02698553 | Depressive Disorder, Major | Drug: Bupropion HCl XL tablet 150mg|Drug: Bupropion HCl XL tablet 300mg | GlaxoSmithKline | Phase 1 | 2016-05-01 | 2016-07-15 |
| NCT01111149 | Schizophrenia|Smoking Cessation | Other: Sugar Pill|Drug: Varenicline|Drug: Bupropion HCl | University of Minnesota - Clinical and Translational Science Institute|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA) | Phase 2 | 2009-12-01 | 2014-07-08 |
| NCT01046214 | Depressive Disorder | Drug: Bupropion HCl|Drug: Bupropion HCl | Teva Pharmaceuticals USA | Phase 1 | 2010-01-01 | 2015-11-19 |
| NCT00883155 | Healthy | Drug: Bupropion HCl 100 mg Tablets (Invamed Inc.)|Drug: Wellbutrin 100 mg Tablets (Glaxo Wellcome) | Sandoz | Phase 1 | 1998-10-01 | 2009-04-16 |
| NCT00689611 | Acute Coronary Syndrome|Myocardial Infarction|Smoking | Drug: Bupropion HCl ER|Drug: Placebo | Mark Eisenberg|Canadian Institutes of Health Research (CIHR)|Heart and Stroke Foundation of Canada|McGill University | Phase 3 | 2005-12-01 | 2015-04-10 |
| NCT02735603 | Heart Repolarization | Drug: Naltrexone HCl/bupropion HCl|Other: Placebo|Drug: Moxifloxacin | Orexigen Therapeutics, Inc | Phase 1 | 2016-04-01 | 2016-10-31 |
| NCT00865410 | Healthy | Drug: Abrika Bupropion 150 mg Extended-Released Tablet|Drug: Wellbutrin SR 150 mg Extended-Release Tablet, single dose | Actavis Inc. | Phase 1 | 2004-08-01 | 2010-08-13 |
| NCT00064467 | Epilepsy|Major Depressive Disorder (MDD) | Drug: Extended-release bupropion (HCl) | GlaxoSmithKline | Phase 3 | 2003-06-01 | 2017-01-18 |
| NCT02078180 | Depression | Drug: generic bupropion | University of Michigan | Phase 4 | 2014-04-01 | 2016-05-13 |
| NCT00861939 | Depression | Drug: Bupropion HCI 300 mg Extended-Release Tablets EON|Drug: WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline | Sandoz | Phase 1 | 2004-03-01 | 2009-03-13 |
| NCT00248118 | Tobacco Dependence | Drug: Bupropion | National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC) | Phase 2|Phase 3 | 2005-01-01 | 2016-09-22 |
| NCT01648283 | Healthy Volunteers | Drug: racemic methadone HC1|Drug: Oral deuterated racemic methadone HCl, | Washington University School of Medicine | | 2012-05-01 | 2016-06-16 |
| NCT00322205 | Smoking Cessation | Drug: zyban | National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA) | Phase 4 | 1999-06-01 | 2017-01-10 |
| NCT01526005 | Cigarette Smoking | Drug: Transdermal Nicotine Patch|Drug: Transdermal Placebo Patch | Brentwood Biomedical Research Institute | Phase 3 | 2012-03-01 | 2015-01-26 |
